Last reviewed · How we verify
IPV IM Needle
IPV IM Needle, marketed by the London School of Hygiene and Tropical Medicine, holds a position in the vaccine market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the robustness of its patent protection. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | IPV IM Needle |
|---|---|
| Also known as | Inactivated Poliovirus Vaccine Intramuscular using syringe and needle pair |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- IPV Clinical Trial - The Gambia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPV IM Needle CI brief — competitive landscape report
- IPV IM Needle updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI